Eosinophilic Esophagitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Eosinophilic Esophagitis – Pipeline Review, H2 2016’, provides an overview of the Eosinophilic Esophagitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis

The report reviews pipeline therapeutics for Eosinophilic Esophagitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Eosinophilic Esophagitis therapeutics and enlists all their major and minor projects

The report assesses Eosinophilic Esophagitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adare Pharmaceuticals, Inc.

Calypso Biotech SA

Celgene Corporation

DBV Technologies S.A.

Dr. Falk Pharma GmbH

Novartis AG

Panmira Pharmaceuticals, LLC.

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Eosinophilic Esophagitis Overview 7

Therapeutics Development 8

Pipeline Products for Eosinophilic Esophagitis - Overview 8

Eosinophilic Esophagitis - Therapeutics under Development by Companies 9

Eosinophilic Esophagitis - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Eosinophilic Esophagitis - Products under Development by Companies 13

Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 14

Adare Pharmaceuticals, Inc. 14

Calypso Biotech SA 15

Celgene Corporation 16

DBV Technologies S.A. 17

Dr. Falk Pharma GmbH 18

Novartis AG 19

Panmira Pharmaceuticals, LLC. 20

Quorum Innovations LLC 21

Regeneron Pharmaceuticals Inc 22

Shire Plc 23

Eosinophilic Esophagitis - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

Allergen for Milk Allergy - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AM-211 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AM-461 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

budesonide - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

budesonide - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CALY-002 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

dectrekumab - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

dupilumab - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

fluticasone propionate - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

fluticasone propionate - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Qi-201 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

RPC-4046 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Eosinophilic Esophagitis - Dormant Projects 58

Eosinophilic Esophagitis - Product Development Milestones 59

Featured News & Press Releases 59

Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy 59

Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 59

Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 60

Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 61

Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 61

Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 61

Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 62

May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 63

Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 64

May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 64

May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 65

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Eosinophilic Esophagitis – Pipeline by Adare Pharmaceuticals, Inc., H2 2016 14

Eosinophilic Esophagitis – Pipeline by Calypso Biotech SA, H2 2016 15

Eosinophilic Esophagitis – Pipeline by Celgene Corporation, H2 2016 16

Eosinophilic Esophagitis – Pipeline by DBV Technologies S.A., H2 2016 17

Eosinophilic Esophagitis – Pipeline by Dr. Falk Pharma GmbH, H2 2016 18

Eosinophilic Esophagitis – Pipeline by Novartis AG, H2 2016 19

Eosinophilic Esophagitis – Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 20

Eosinophilic Esophagitis – Pipeline by Quorum Innovations LLC, H2 2016 21

Eosinophilic Esophagitis – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 22

Eosinophilic Esophagitis – Pipeline by Shire Plc, H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Eosinophilic Esophagitis – Dormant Projects, H2 2016 58

List of Figures

List of Figures

Number of Products under Development for Eosinophilic Esophagitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports